The Role of Lactobacillus reuteri DSMZ17648 for Helicobacter pylori eradication therapy (Review of literature and advisory council resolution, February 28, 2018)

Aim of review. To analyze the options of application of Lactobacillus reuteri DSMZ17648 (Pylopass™) within Helicobacter pylori eradication. Summary. H. pylori eradication therapy is considered as one of the optional spheres for clinical application of probiotic medications. According to available data certain strains of probiotics are effective in decreasing of gastrointestinal adverse effects rates, associated with eradication therapy while the other can potentiate the efficacy of H. pylori eradication itself. L. reuteri strain DSM17648 which was chosen from over 700 wildtype strains of Lactobacillus spp. possess the ability for selective adhesion to H. pylori in vivo in the gastric media. DSM17648 strain of L. reuteri form coaggregates with various H. pylori strains and serotypes both in vivo and in vitro. It was revealed that lyophilizate of this strain (PylopassTM) blocks adhesion of H. pylori to epithelial cells as well. Clinical trials demonstrate the effect of PylopassTMon gastric mucosa colonization by H. pylori according to the 13C urea breath test data and as well the increase in H. pylori eradication rate when the productis added the to triple therapy modes. Conclusion. Potential of PylopassTM combination to various H. pylori eradication therapy modes is a subject offutnet multicenter randomized clinical trials for assessment of optimal combination to antibiotic drugs, treatment duration and adverse effect rates. The value of monotherapy by this metabiotic at chronic H. pyloriassociated gastritis is a subject of further studies.

Lactobacillus reuteri, пробиотик, метабиотик, Helicobacter pylori

1. Malfertheiner P., Megraud F., O’Morain C.A., Gisbert J.P., Kuipers E.J. et al. Management of Helicobacter pylori infection the Maastricht V/ Florence Consensus Report. Gut 2017;66:6-30.

2. WGO Practice Guideline Probiotics and Prebiotics http://www.worldgastroenterology.org

3. Ивашкин В.Т., Маев И.В., Лапина Т.Л., Шептулин А.А., Трухманов А.С., Баранская Е.К., Абдулхаков Р.А., Алексеева О.П., Алексеенко С.А., Дехнич Н.Н., Козлов Р.С., Кляритская И.Л., Корочанская Н.В., Курилович С.А., Осипенко М.Ф., Симаненков В.И., Ткачев А.В., Хлынов И.Б., Цуканов В.В. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. Рос журн гастроэнтерол гепатол колопроктол 2018; 28(1):55-70.

4. Lv Z., Wang B., Zhou X. et al. Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: a meta-analysis. Exp Ther Med 2015; 9:707-16.

5. Tong J.L., Ran Z.H., Shen J. et al. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2007; 25:155-68.

6. Wang Z.H., Gao Q.Y., Fang J.Y. Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy. J Clin Gastroenterol 2013; 47:25-32.

7. Zhang M-M., Qian W., Qin Y-Y. et al. Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis. World J Gastroenterol 2015; 21:4345-57.

8. Zheng X., Lyu L., Mei Z. Lactobacillus-containing probiotic supplementation increases Helicobacter pylori eradication rate: evidence from a meta-analysis. Rev Esp Enferm Dig 2013; 105:445-53.

9. Zhu R., Chen K., Zheng Y.-Y. et al. Meta-analysis of the efficacy of probiotics in Helicobacter pylori eradication therapy. World J Gastroenterol 2014; 20:18013-21.

10. Dang Y., Reinhardt J.D., Zhou X., Zhang G. The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: a meta-analysis. PloS One 2014;9(11): e111030.

11. McFarland L.V., Huang Y., Wang L., Malfertheiner P. Systematic review and meta-analysis: Multi-strain probiotics as adjunct therapy for Helicobacter pylori eradication and prevention of adverse events. United Eur Gastroenterol J 2016;4(4):546-61.

12. McFarland L.V., Malfertheiner P., Huang Y. et al. Meta-analysis of single strain probiotics for the eradication of Helicobacter pylori and prevention of adverse events. World J Meta-anal 2015; 3:97-117.

13. Tyagi A.K., Prasad S. Commentary: Probiotic and technological properties of Lactobacillus spp. strains from the human stomach in the search for potential candidates against gastric microbial dysbiosis. Front Microbiol 2015;6:433.

14. Delgado S. et al. Probiotic and technological properties of Lactobacillus spp. strains from the human stomach in the search for potential candidates against gastric microbial dysbiosis. Front Microbiol 2014; 5: 766.

15. Mehling H., Busjahn A. Non-viable Lactobacillus reuteri DSMZ 17648 (Pylopass™) as a new approach to Helicobacter pylori control in humans. Nutrients 2013;5(8):3062-73. doi: 10.3390/nu5083062.

16. Holz C. et al. Significant Reduction in Helicobacter pylori Load in Humans with Non-viable Lactobacillus reuteri DSM17648: A Pilot Study. Probiot Antimicrob Proteins 2015;7(2):91-100.

17. Бордин Д.С., Войнован И.Н., Хомерики С.Г., Янова О.Б. и др. Эффективность и безопасность L. reuteri DSMZ17648 у инфицированных Helicobacter pylori, не имеющих абсолютных показаний для эрадикационной терапии. Леч врач 2016; 5:1-6.

18. Ивашкин В.Т., Никитина Е.И., Степанов Е.В., Понуровский Я.Я., Селиванов Ю.Г. 13С-уреазный дыхательный тест на основе лазерной спектроскопии: клиническая апробация. Рос журн гастроэнтерол гепатол колопроктол 1999; 9(2):53-60.

19. Никитина Е.И. Диагностика инфекции Helicobacter pylori и лечение хронического Helicobacter pyloriассоциированного гастрита: Автореф. дис. … канд мед. наук. М.; 1999. 23 с.

20. Паролова Н.И., Корниенко Е.А., Антонов П.В., Егорова М.Б., Горбунов Е.Ф., Дмитриенко М.А. Инновационный подход в терапии инфекции Н. pylori у детей. Рус мед журн 2015; 22:2-3.

21. Успенский Ю.П., Фоминых Ю.А, Иванов С.В., Менакер И.О. Эволюция в эрадикационной терапии НР-ассоциированных заболеваний. Выход за рамки стандартов? Рус мед журн 2016: https://www.rmj.ru/articles/ gastroenterologiya/Evolyuciya_v_eradikacionnoy_ terapii_NRassociirovannyh_zabolevaniy_Vyhod_za_ ramki_standartov/#ixzz58a4nggA .